DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: naproxen sodium

Summary for Generic Name: naproxen sodium

Tradenames:8
Patents:5
Applicants:28
NDAs:37
Drug Master File Entries: see list42
Suppliers: see list38
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: naproxen sodium

Clinical Trials for: naproxen sodium

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
Status: Completed Condition: Migraine With or Without Aura; Migraine Disorders; Migraine, Acute; Migraine Headaches

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan
Status: Completed Condition: Pharmacokinetics

Naproxen Codeine in Arthroscopic Surgery
Status: Completed Condition: Arthroscopic Meniscus Surgery

Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination
Status: Completed Condition: Therapeutic Equivalence

Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium
Status: Completed Condition: Pain, Postoperative

Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fasting Conditions
Status: Completed Condition: Healthy

Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone
Status: Completed Condition: Healthy

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels
Status: Completed Condition: Arthritis

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine
Status: Completed Condition: Sleep

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Smithkline Beecham
TREXIMET
naproxen sodium; sumatriptan succinate
TABLET;ORAL021926Apr 15, 2008RXYes8,022,095<disabled>YTREATMENT OF MIGRAINE
Smithkline Beecham
TREXIMET
naproxen sodium; sumatriptan succinate
TABLET;ORAL021926Apr 15, 2008RXYes7,332,183<disabled>YTREATMENT OF MIGRAINE
Smithkline Beecham
TREXIMET
naproxen sodium; sumatriptan succinate
TABLET;ORAL021926Apr 15, 2008RXYes6,586,458<disabled>YTREATMENT OF MIGRAINE
Smithkline Beecham
TREXIMET
naproxen sodium; sumatriptan succinate
TABLET;ORAL021926Apr 15, 2008RXYes6,060,499<disabled>YTREATMENT OF MIGRAINE
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc